Autologous tumour infiltrating lymphocytes cell therapy in metastatic non-small cell lung cancer

Incorporating KRAS as a novel biomarker: Challenges and opportunities

Real world data and diagnostics in patients with NSCLC with EGFR exon 20 insertions

Durvalumab following radiotherapy in patients with unresectable, stage 3 NSCLC ineligible for chemotherapy

Neo-adjuvant therapy and surgical decision making in breast cancer

Nurse's perspective on PARP inhibitors and personalised medicine in prostate cancer

COVID-19 pandemic threatens global life-saving gains in childhood cancer

Emergence of PARP inhibitors in prostate cancer

OncoAlert and ecancer weekly roundup for January 25 - 31, 2021

WCLC 2020: Updates from the CHRYSALIS trial and what it means for patients with NSCLC

New data from rare EGFR alterations in NSCLC from WCLC 2020

A new way of thinking on the origin of breast cancer and how early breast cancer should be treated